| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 727.10M | 757.10M | 802.50M | 743.60M | 615.80M | 598.00M |
| Gross Profit | 100.50M | 109.30M | 108.10M | 269.70M | 225.70M | 186.90M |
| EBITDA | 176.80M | 124.00M | 201.70M | 186.60M | 167.70M | 97.00M |
| Net Income | 28.40M | 20.00M | 85.60M | 73.70M | 59.50M | 400.00K |
Balance Sheet | ||||||
| Total Assets | 1.05B | 1.07B | 1.14B | 1.17B | 1.07B | 1.11B |
| Cash, Cash Equivalents and Short-Term Investments | 20.20M | 19.10M | 45.20M | 37.20M | 39.30M | 30.70M |
| Total Debt | 190.50M | 150.90M | 96.90M | 136.60M | 156.20M | 128.80M |
| Total Liabilities | 406.70M | 397.50M | 344.40M | 385.70M | 384.40M | 428.60M |
| Stockholders Equity | 639.40M | 668.10M | 790.80M | 780.90M | 684.70M | 680.50M |
Cash Flow | ||||||
| Free Cash Flow | 70.40M | 82.50M | 109.20M | 70.10M | 87.10M | 74.50M |
| Operating Cash Flow | 146.70M | 152.60M | 191.60M | 137.10M | 139.10M | 134.40M |
| Investing Cash Flow | -64.20M | -112.80M | -71.20M | -62.30M | -104.80M | -124.70M |
| Financing Cash Flow | -74.40M | -67.60M | -110.20M | -82.80M | -30.30M | -6.30M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £5.99B | 26.00 | 23.79% | 1.30% | -0.32% | -3.96% | |
75 Outperform | £7.25B | 23.68 | 17.68% | 0.58% | -1.97% | 40.55% | |
73 Outperform | £1.43B | 36.18 | 35.23% | 1.06% | 24.42% | 103.25% | |
72 Outperform | £4.90B | 30.15 | 14.19% | 2.43% | 0.10% | -15.33% | |
69 Neutral | £1.22B | 44.43 | 4.10% | 3.22% | -6.95% | -52.08% | |
67 Neutral | £588.09M | 21.46 | 8.04% | 4.84% | -7.30% | -59.71% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
Bodycote has announced a new divisional reporting structure as part of its expanded Optimise programme, which now includes 30 plants. This restructuring aims to deliver a profit benefit of at least £15 million by mid-2027, with a net cash cost of £10-15 million. The reclassification of additional plants as Non-Core is expected to enhance operational efficiency and financial performance, impacting the company’s future reporting and potentially its market positioning.
Bodycote reported a modest organic revenue growth of 2.2% in its core business for the four-month period ending October 2025, despite challenges in the Automotive and Industrial sectors. The company is progressing with its Optimise programme, including the sale of 10 French sites and plant closures, which is expected to enhance operational efficiency and profitability. Strong growth in the Aerospace & Defence sector and strategic investments in Precision Heat Treatment and HIP capacity are anticipated to drive future growth, with a focus on improved operational execution and potential acquisitions.
Bodycote plc has announced a continuation of its share buyback program, purchasing 36,188 of its ordinary shares at a volume-weighted average price of 635.87 pence per share. This move, part of an extended program, aims to cancel the repurchased shares, reducing the total number of shares in issue to 175,699,513, thereby potentially increasing shareholder value and consolidating its market position.
Bodycote plc has announced the continuation of its share buyback program, purchasing 36,248 ordinary shares at a volume-weighted average price of 635.77 pence per share. This move is part of an extended program aimed at reducing the number of shares in circulation, thereby potentially increasing the value of remaining shares and strengthening the company’s market position.